With FDA Approval for Advanced Lymphoma, Second CAR T-Cell Therapy Moves to the Clinic

| October 25, 2017 | 0 Comments
With FDA Approval for Advanced Lymphoma, Second CAR T-Cell Therapy Moves to the Clinic

One month after approving the first CAR T-cell therapy for cancer, FDA has approved a second such therapy. The treatment, axicabtagene ciloleucel (Yescarta™), was approved for some patients with advanced non-Hodgkin lymphoma.
See Original Article

Category: Recent News

About the Author ()

Leave a Reply